ArticleThe New England journal of medicine2012
Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms.
Article in The New England journal of medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06414681 (An Open Label Pilot Trial of the Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined), which is not on this map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open Label Pilot Trial of the Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined
Who cites it
30 citing papers in PubMed, 66 citations in OpenAlex.
- Allosteric inhibition of JAK2 with lysine-reactive compounds that bind the pseudokinase domain.European journal of medicinal chemistry · 2026Article
- Efficient Approaches to the Design of Six-Membered Polyazacyclic Compounds-Part 1: Aromatic Frameworks.Molecules (Basel, Switzerland) · 2025Review
- Treatment Strategies Used in Treating Myelofibrosis: State of the Art.Hematology reports · 2024Review
- Article
- Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape.Cancer research · 2022Article
- The JAK2 inhibitor TG101209 exhibits anti-tumor and chemotherapeutic sensitizing effects on Burkitt lymphoma cells by inhibiting the JAK2/STAT3/c-MYB signaling axis.Cell death discovery · 2021Article
- Developing strategies to reduce the duration of therapy for patients with myeloproliferative neoplasms.Expert review of hematology · 2020Article
- Article
- Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy.Blood · 2018Article
- Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation.Journal of clinical immunology · 2018Article
- JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.F1000Research · 2018Review
- β-Arrestin2 mediates progression of murine primary myelofibrosis.JCI insight · 2017Article
- Review
- Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases.Oncotarget · 2017Article
- Review
- Developmental Therapeutics in Myeloproliferative Neoplasms.Clinical lymphoma, myeloma & leukemia · 2017Review
- Article
- JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice.Journal of cellular and molecular medicine · 2015Article
- Review
- Translational horizons in the tumor microenvironment: harnessing breakthroughs and targeting cures.Medicinal research reviews · 2015Review
Corrections and comments
- Commented on by
- Comment on
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.